Regional changes over time in initial virological response rates to combination antiretroviral therapy across Europe.

W Bannister, O Kirk, J Gatell, B Knysz, J-P Viard, H Mens, A D´arminio Monforte, A Phillips, A Mocroft, Jens Dilling Lundgren

    Abstract

    BACKGROUND: Changes in virologic response to initial combination antiretroviral therapy (cART) over calendar time may indicate improvements in cART or emergence of primary resistance. Regional variations may identify differences in available antiretroviral drugs or patient management. METHODS: Virologic response (viral load < 500 copies/mL) 6 to 12 months after starting cART was analyzed in antiretroviral-naive EuroSIDA patients. Analyses were stratified by region (south, central west, north, east) or time started cART (early, 1996-1997; mid, 1998-1999; late, 2000-1904). RESULTS: Virologic suppression was achieved by 60% of 2102 patients: 57% south (n = 560), 61% central west (n = 466), 63% north (n = 606), 58% east (n = 470) (P = 0.091). An increase was observed over time: 52% early cART, 56% mid cART, 69% late cART (P < 0.001). Overall, there were significant effects of region (P = 0.026) and time (P < 0.001) on virologic response after adjustment for confounders. Stratified by period, regional differences were less evident (early cART, P = 0.967; mid cART, P = 0.291; late cART, P = 0.163). Stratified by region, temporal changes were observed (south, P = 0.061; central west, P < 0.001; north: P = 0.070; east, P = 0.001). CONCLUSIONS: There was some evidence of regional differences in initial virologic response to cART. Improvements over time were observed, suggesting that so far, the effect of primary resistance has not been of sufficient magnitude to prevent increasing suppression rates.
    Original languageEnglish
    JournalJ Acquir Immune Defic Syndr.
    Volume42
    Issue number2
    Pages (from-to)229-37
    ISSN0894-9255
    Publication statusPublished - 2006

    Fingerprint

    Dive into the research topics of 'Regional changes over time in initial virological response rates to combination antiretroviral therapy across Europe.'. Together they form a unique fingerprint.

    Cite this